PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology

Alzheimer’s disease (AD) is a progressive irreversible neurodegenerative disorder that represents a major global public health concern. Traditionally, AD is diagnosed using cerebrospinal fluid biomarker analysis or brain imaging modalities. Recently, less burdensome, more widely available blood biom...

Full description

Bibliographic Details

Published in:	Diagnostics
Main Authors:	Stephanie M. Eastwood, Matthew R. Meyer, Kristopher M. Kirmess, Traci L. Wente-Roth, Faith Irvin, Mary S. Holubasch, Philip B. Verghese, Tim West, Joel B. Braunstein, Kevin E. Yarasheski, John H. Contois
Format:	Article
Language:	English
Published:	MDPI AG 2024-08-01
Subjects:	Alzheimer’s biomarker blood biomarker test diagnostic tool mass spectrometry analytical methods/validity brain amyloid plaques
Online Access:	https://www.mdpi.com/2075-4418/14/16/1739